Immatics (IMTX) had the highest return in the 2010s by a US stock in the Biotechnology Industry, returning 207,900%.
| ASSET | DECADE | % RETURN |
|---|---|---|
Immatics (IMTX) | 2010s | 207,900% |
AquaBounty Technologies (AQB) | 2010s | 30,038.89% |
Neurocrine Biosciences (NBIX) | 2010s | 3,780.51% |
ACADIA Pharmaceuticals (ACAD) | 2010s | 3,140.91% |
EXACT Sciences (EXAS) | 2010s | 2,542.29% |
Travere Therapeutics (TVTX) | 2010s | 1,477.78% |
Regeneron Pharmaceuticals (REGN) | 2010s | 1,449.01% |
Amarin (AMRN) | 2010s | 1,399.3% |
Sarepta Therapeutics (SRPT) | 2010s | 1,353.15% |
Galapagos NV ADR (GLPG) | 2010s | 1,312.19% |
Genmab A-S (GMAB) | 2010s | 1,237.13% |
Arrowhead Pharmaceuticals (ARWR) | 2010s | 1,096.79% |
Avita Medical (RCEL) | 2010s | 943.03% |
MiMedx (MDXG) | 2010s | 938.36% |
Incyte (INCY) | 2010s | 847.07% |
argenx NV ADR (ARGX) | 2010s | 796.76% |
Ligand Pharmaceuticals (LGND) | 2010s | 765.38% |
Evotec SE ADR (EVO) | 2010s | 709.04% |
Kodiak Sciences (KOD) | 2010s | 619.5% |
Anika Therapeutics (ANIK) | 2010s | 576.89% |
InMed Pharmaceuticals (INM) | 2010s | 566.67% |
Ascendis Pharma A-S (ASND) | 2010s | 547.07% |
Alnylam Pharmaceuticals (ALNY) | 2010s | 545.57% |
Catalyst Pharmaceuticals (CPRX) | 2010s | 490.55% |
Xencor (XNCR) | 2010s | 477.98% |
